WARRINGTON, Pa. – Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology company developing therapies for critical conditions, today announced the addition of Leanne Kelly to its board of directors. Kelly, who is currently Chief Financial Officer at GRI Bio, brings more than two decades of experience in finance within the life sciences, technology and e-commerce sectors. According to InvestingPro according to the data, the company is facing significant financial challenges with a current ratio of 0.27, indicating potential liquidity concerns.
Kelly’s appointment as an independent director and chairman of the audit committee is part of Windtree’s broader strategy to transition into a revenue-generating biotech company. According to Windtree CEO Jed Latkin, Kelly’s expertise is expected to strengthen the board’s capabilities as the company looks to expand by acquiring smaller biotech companies with FDA-approved products. With a market cap of just $2.29 million and an EBITDA of -$24.68 million over the last twelve months, InvestingPro analysis shows that the company is currently undervalued, although it faces significant operational challenges. (Discover more insights with InvestingPro’s 15+ Additional WINT Tips.)
With a history of financial leadership roles in companies such as Vallon Pharmaceuticals and OptiNose (NASDAQ:), Inc., Kelly’s addition to the board is considered a strategic move for Windtree. Her work in various senior financial positions, along with her academic background from Lehigh University and her CPA credentials, are expected to contribute to the company’s financial and strategic planning.
Windtree is currently advancing a number of product candidates, including istaroxime for acute heart failure, and has a licensing business model with existing partner external licenses. The company’s focus remains on clinical development programs for various candidates, including preclinical oncology candidates. Financial metrics from InvestingPro show that the company is spending money quickly, with a negative free cash flow of -$15.3 million, highlighting the importance of strategic financial management in the development phase.
The information in this article is based on a press release from Windtree Therapeutics.
In other recent news, Windtree Therapeutics, a biotech company, unveiled a new acquisition strategy aimed at becoming a revenue-generating entity. The company plans to acquire smaller companies with FDA-approved products to build its commercial portfolio as it continues to develop its cardiovascular and oncology pipelines. Windtree Therapeutics also faces challenges in complying with Nasdaq’s listing standards, following the appointment of Jed Latkin as president and chief executive officer, which reduced the number of audit committee members.
The company has undergone significant changes in executive leadership, with CEO Craig Fraser announcing his retirement and Jed Latkin to succeed him. Windtree Therapeutics disclosed a potential sale of up to $27.24 million of its common stock to Seven Knots, LLC. The company has also completed national-stage patent applications for its istaroxime treatment, designed to treat cardiogenic shock, in several countries, including a Japanese patent that will remain in effect until 2039.
Windtree Therapeutics reported positive results from its SEISMiC Phase 2b expansion study and is gearing up for a Phase 3 trial readiness in the area of cardiogenic shock. Additionally, Jamie McAndrew was named Senior Vice President and Chief Financial Officer, and new independent directors, Saundra Pelletier and Jed Latkin, were added to the board. Finally, analyst firm HC Wainwright maintained a Neutral rating on Windtree Therapeutics.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
